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Abstract
Background: Photodynamic therapy (PDT) involves the administration of a tumor-localizing
photosensitizing drug, which is activated by light of specific wavelength in the presence of molecular
oxygen thus generating reactive oxygen species that is toxic to the tumor cells. PDT selectively
destroys photosensitized tissue leading to various cellular and molecular responses. The present
study was designed to examine the angiogenic responses at short (0.5 h) and long (6 h) drug light
interval (DLI) hypericin-PDT (HY-PDT) treatment at 24 h and 30 days post treatment in a human
bladder carcinoma xenograft model. As short DLI targets tumor vasculature and longer DLI
induces greater cellular damage, we hypothesized a differential effect of these treatments on the
expression of angiogenic factors.
Results: Immunohistochemistry (IHC) results showed minimal CD31 stained endothelium at 24 h
post short DLI PDT indicating extensive vascular damage. Angiogenic proteins such as vascular
endothelial growth factor (VEGF), tumor necrosis growth factor-α (TNF-α), interferon-α (IFN-α)
and basic fibroblast growth factor (bFGF) were expressed to a greater extent in cellular targeting
long DLI PDT compared to vascular mediated short DLI PDT. Gene expression profiling for
angiogenesis pathway demonstrated downregulation of adhesion molecules – cadherin 5, collagen
alpha 1 and 3 at 24 h post treatment. Hepatocyte growth factor (HGF) and Ephrin-A3 (EFNA3)
were upregulated in all treatment groups suggesting a possible activation of c-Met and Ephrin-Eph
signaling pathways.
Conclusion:  In conclusion, long DLI HY-PDT induces upregulation of angiogenic proteins.
Differential expression of genes involved in the angiogenesis pathway was observed in the various
groups treated with HY-PDT.
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Background
Photodynamic therapy (PDT) is a cytotoxic treatment,
predominantly used in anti-cancer approaches, that
depends on the retention of photosensitizers in tumor
and its subsequent activation by light [1]. The tumor
response to PDT is complex; involving vascular damage,
direct tumor cell death, and the induction of immune
responses that greatly depend on the photosensitizer
pharmacokinetics and the treatment conditions [2]. Blad-
der cancer is the fifth most common malignancy in
Europe and the fourth most in the United States, and the
main thrust of research is to prevent the progression of
superficial cancers to metastatic tumors [3]. PDT has been
shown to induce complete or partial destruction of tumor,
reducing recurrence rate in bladder cancer patients [4].
Hypericin (HY), a perylenequinone with potent photo-
sensitizing properties induces in vivo and in vitro photocy-
totoxic activity and displays potential as a photosensitizer
for PDT [5-7]. Our previous study reported the use of HY
as a selective marker for the diagnosis of bladder tumors
in clinical trials [8].
The preference of vascular versus cellular targeting of PDT
treatment is highly dependent upon the relative distribu-
tion of the photosensitizer in the vascular and cellular
compartments and can also be effectively manipulated by
varying the drug and light intervals (DLI). Initially after
photosensitizer is administered, the drug is confined
within the tumor vasculature and employing a short DLI
largely damages the tumor vasculature. However during
longer DLI the photosensitizer diffuses out from the
blood vessels into the tissue, and accumulates in the
tumor cellular compartment and the subsequent light
irradiation targets the cells and causes tumor cytotoxicity
[9-11]. Vascular damage has been implicated as the pri-
mary antitumoral effect in PDT with various photosensi-
tizers [12], including HY [10]. An earlier study by our
group had shown that vascular damage and direct cell kill-
ing together with a strong inflammatory response contrib-
ute towards tumor necrosis and shrinkage following PDT
in nasopharyngeal tumors [13]. It is believed that the cir-
culating photosensitizer in the plasma generates cytotoxic
reactive oxygen species, which leads to primary vascular
damage that result in tumor necrosis. It has also been
acknowledged that targeting tumor vasculature proves to
be a promising approach in cancer treatment [14].
As part of the PDT process, hypoxia is induced in tumors
and this oxidative stress initiates a variety of molecular
and physiological responses that could potentially lead to
neovascularisation. Angiogenesis, the formation of new
blood vessels from existing vasculature, is a multistep
process involving the degradation of extracellular matrix,
endothelial cell proliferation, migration and tube forma-
tion [15,16]. Our studies as well as other reports have
observed the overexpression of angiogenic markers after
PDT treatment [17-20]. The response of both vascular and
cellular targeted PDT and the combination of both has
been well documented by Chen et al. [9-11]. Though pre-
vious studies have shown different mechanistic aspects of
vascular and cellular mediated PDT, little is known about
the angiogenic responses in these treatment variations. In
this study we investigated the effect of short and long DLI
in modulating the mechanism of angiogenesis in tumors.
Our results revealed differential expression of several pro-
teins and genes involved in various angiogenic processes,
i.e. proliferation, inflammation and carcinogenesis in
response to HY-PDT of bladder carcinoma.
Results
Hypericin macrofluorescence
Hypericin fluorescence in the tumor was evaluated using
a fluorescence endoscopy system to determine the uptake
kinetics in the tumor at 0.5 and 6 h post drug administra-
tion. Fluorescence intensity in the tumor was higher at 6
h compared to 0.5 h post HY administration suggesting
higher tumor selectivity (Fig. 1A). At 6 h fluorescence in
muscle and skin was lower indicating higher clearance
from normal tissue. The tumor to normal tissue ratio tab-
ulated from the fluorescence images was greater at 6 h
compared to 0.5 h post HY administration, p < 0.01 (Fig.
1B).
Hypericin microfluorescence
Hypericin microfluorescence was detected using a confo-
cal laser scanning microscope to establish the correlation
between macro and microfluorescence observed in the
tumors at 0.5 and 6 h post drug administration. Micro-
scopic fluorescence of HY in the tumor was significantly
higher at 6 h compared to 0.5 h time point (Fig. 2A). Flu-
orescence increased twofold at 6 h post HY administration
compared to 0.5 h, p < 0.01 (Fig. 2B).
Tumor volume assessment
Tumors were allowed to grow up to sizes of 6–7 mm in
diameter before PDT treatment was carried out, and were
measured three times a week. Animals subjected to vascu-
lar targeted short DLI PDT exhibited greater tumor
response compared to cellular targeted long DLI PDT, p <
0.05 and control, p < 0.01 (Fig. 3). The decrease in growth
rate in short DLI PDT group is indicative of significant
damage to the tumor vasculature during treatment.
Immunohistochemistry
Blood vessel staining was performed to calculate vessel
density after HY-PDT treatment. Immunohistochemistry
revealed highest endothelium density at 24 h after long
DLI PDT (IHC score 4) (Fig. 4C), however at 24 h post
short DLI PDT, lesser smudged and diffused staining pat-
tern (IHC score 2) of endothelial cells were noted (Fig.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
Page 3 of 14
(page number not for citation purposes)
4B). Moderate staining (IHC score 1) of blood vessels
were observed in control, short and long DLI PDT 30 days
treated tumors (Fig 4A, D, E).
Western immunoblotting
Blotting of angiogenic proteins, i.e. VEGF, TNF-α and IFN-
α was carried out to understand the modulations in pro-
tein expression at 24 h and 30 days post PDT treatment.
TNF-α was significantly downregulated at 30 days post
vascular targeted short DLI PDT compared to all other
treatment groups. Expression of VEGF and IFN-α was sig-
nificantly upregulated in long DLI 24 h group compared
to all other groups (p < 0.05) (Fig 5A, B).
Detection of angiogenic proteins using antibody arrays
Expression of major angiogenic proteins i.e., VEGF, bFGF,
IFN-γ and IL-6 were detected in the treatment groups
using human angiogenesis antibody arrays. VEGF expres-
sion was significantly greater (p < 0.05) in the treatment
groups compared to control tumors. bFGF expression was
significantly greater in vascular mediated short DLI PDT
compared to cellular mediated long DLI PDT groups. IFN-
γ expression was most pronounced at 30 days in the long
DLI PDT group. Upregulation of inflammatory protein IL-
6 was remarkably higher compared to all other angiogenic
proteins. At 24 h post PDT significantly high levels of IL-6
were expressed (Fig. 6).
Real-Time PCR to detect expression of genes involved in 
angiogenesis pathways
Gene expression of different genes involved in angiogen-
esis was assessed to understand the role of transcriptional
factors before tumor regrowth. Adhesion molecules i.e.,
cadherin 5 (CDH5) and collagens (COL18A1 and
COL4A3) were downregulated 24 h post vascular targeted
short DLI PDT and cellular targeted long DLI PDT, how-
ever at 30 days post treatment CDH5 and COL18A1 were
upregulated with the exception of COL4A3. Intergrin
alpha V (ITGAV) and Intergrin beta 3 (ITGB3) were down-
regulated in short and long DLI PDT at 24 h, however
increased mRNA transcription was noticed at 30 days time
point with the exception of ITGAV that was downregu-
lated at short DLI PDT. Ephrin A3 (EFNA3) and Ephrin B2
(EFNB2) are ligands of the eph receptor family that plays
A, Representative red fluorescence images of tumor, muscle and skin at 0.5 h and 6 h post HY administration shows increased  uptake in the tumor at 6 h time point compared to 0.5 h Figure 1
A, Representative red fluorescence images of tumor, muscle and skin at 0.5 h and 6 h post HY administration shows increased 
uptake in the tumor at 6 h time point compared to 0.5 h. B, Tumor to normal tissue ratio was greater at 6 h compared to 0.5 
h post HY administration, p < 0.01, indicating greater tumor uptake. Each group represents the mean (bars, SE) of 8 animals.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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A, Microfluorescence of HY in the tumor at 0.5 h and 6 h was detected using confocal laser scanning microscope Figure 2
A, Microfluorescence of HY in the tumor at 0.5 h and 6 h was detected using confocal laser scanning microscope. HY fluores-
cence in the tumor was increased at 6 h compared to 0.5 h time point. B, In correlation with the macrofluorescence data, 
quantification of HY fluorescence at 0.5 h and 6 h clearly indicated greater uptake at 6 h, p < 0.01. Each group represents the 
mean (bars, SE) of 8 animals.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
Page 5 of 14
(page number not for citation purposes)
a major role in tumor remodeling. Ephrin A3 was upregu-
lated at 24 h post PDT, however ephrin B2 was downreg-
ulated. Both EFNA3 and EFNB2 were overexpressed 30
days post PDT treatment. Hepatocyte growth factor (HGF)
expression was found to be 4-fold greater than epidermal
growth factor (EGF) at 24 h post vascular mediated short
DLI PDT. HGF acts through the Met-receptor pathway to
promote angiogenesis and its transcription was well pro-
nounced in all our PDT treated groups. EGF induced sign-
aling has often been associated with tumor invasion and
metastasis. In our experiments, EGF was significantly
overexpressed at 24 h in vascular targeting short DLI PDT
and was downregulated in all other treatment groups.
Increased expression of platelet-derived growth factor
alpha (PDGFA) was observed in all the treatment groups.
Neuropilin 2 (NRP2), a nonsignaling transmembrane
receptor was suppressed only at 30 days post long DLI
PDT. The notch ligand Jagged 1 (JAG1) was downregu-
lated in all the treatment groups. TEK tyrosine kinase
(TEK) was significantly upregulated at 30 days post short
DLI PDT only. Angiogenesis growth factors such as trans-
forming growth factor alpha (TGFA) and vascular
endothelial growth factor C (VEGF-C) were downregu-
lated 24 h post PDT but were upregulated by 30 days.
Tumor necrosis factor, alpha induced protein 2
(TNFAIP2) was downregulated only at 24 h post long DLI
PDT. The function of each gene is provided in Table 1, and
fold change and p-values for the genes are provided in
Tables 2 and 3.
Discussion
It is evident from the present study that short and long
DLI PDT induces differential expression of angiogenic
proteins and genes in bladder carcinoma tumors. In order
to understand the in vivo uptake kinetics of HY, which
depends on its physicochemical and pharmacokinetic
properties, macroscopic and microscopic fluorescence of
HY were examined. At 6 h post HY administration the
intensity of both macro and microfluorescence in the
tumor was significantly greater compared to 0.5 h. By 6 h
post HY administration, the drug rapidly diffuses from the
blood vessels and selectively accumulates in the tumor tis-
sue and similar findings have been reported in radiation-
induced fibrosarcoma (RIF-1) tumors [21]. Based on the
distribution of HY in the tumor, PDT in our experiments
was conducted at 0.5 h (short DLI) and 6 h (long DLI) to
target the vasculature and tumor cells respectively. At
short DLI, the damage is more vascular targeted and at
long DLI greater cellular damage is expected. Our tumor
regression experiments conducted in the bladder carci-
noma xenograft model showed that short DLI PDT which
causes greater vascular damage can improve tumor
response compared to the tumors treated with long DLI
PDT. Also the two time points 24 h and 30 days were cho-
sen to study the immediate and long time effects of PDT
on the angiogenic response.
To assess the status of vasculature, CD31 staining was
used to visualize and enumerate the blood vessels. At 24
h short DLI PDT CD31 staining of congested nonfunc-
tional blood vessels were observed showing evidence of
maximum vascular damage and at long DLI PDT, func-
tional blood vessels were noticed at 24 h post PDT dem-
onstrating greater cellular destruction than vascular
damage at longer DLI PDT. At 30 days the short DLI PDT
effect on the tumor diminished and minimal staining was
observed, however comparably higher CD31-stained
blood vessels were noticed in long DLI PDT, suggesting
neovessel formation and tumor regrowth. Similar to our
studies, extensive vascular damage assessed by CD31
staining was observed by 24 h after PDT treatment in
colon-26 murine tumors [22].
PDT-induced inflammatory changes are characterized by
enhanced expression of a number of angiogenic mole-
cules and proinflammatory cytokines as reported in ear-
lier studies [17,19,20]. We investigated the expression of
angiogenic proteins by employing western blotting and
antibody arrays techniques. IL-6 protein was rapidly and
strongly enhanced in the PDT treated tumors at 24 h sug-
gesting a strong immune response which potentiates anti-
tumor immunity. Our results confirm the enhancement
of IL-6 post PDT as described earlier by Gollnick et al.
[23]. Also upregulation of IL-6 was observed in Photofrin®
photosensitization of HeLa cells [24] and EMT6 cells [25].
Tumor volume charted against treatment days for control,  short DLI and long DLI HY-PDT treated bladder carcinoma  xenografts Figure 3
Tumor volume charted against treatment days for control, 
short DLI and long DLI HY-PDT treated bladder carcinoma 
xenografts. The tumors treated with short DLI PDT exhib-
ited greater tumor control compared to long DLI PDT (p < 
0.05) and control (p < 0.01). Each group represents the mean 
(bars, SE) of 10 animals.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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CD31 expression was assessed in tumors treated with various treatment regimens using immunohistochemistry Figure 4
CD31 expression was assessed in tumors treated with various treatment regimens using immunohistochemistry. A – Control 
(untreated tumor), B – Short DLI 24 h, C – Long DLI 24 h, D – Short DLI 30 days, E – Long DLI 30 days. Control, short DLI 
30 days and long DLI 30 days tumor sections exhibited 8 to 10% staining. In short DLI PDT at 24 h 10% staining of damaged 
vessels were noted. Around 51% CD31 expression was observed in the long DLI 24 h PDT group, (magnification ×200).Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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Increased expression of VEGF, TNF-α, bFGF and IFN-α
and -γ was observed in long DLI compared to short DLI
PDT at 24 h post irradiation. VEGF expression could be
upregulated by PDT induced hypoxia in the tumor cells as
long DLI PDT causes greater cellular damage [19,26]. As
TNF-α is secreted by resident macrophages and stromal
cells following stimulation, the tumor cells under oxida-
tive stress at 6 h DLI PDT could have enhanced the expres-
sion of TNF-α. Increased TNF-α after PDT has been
reported by Gomer et al. [27], their group also demon-
strated the upregulation of cytokines post photofrin PDT.
Interestingly, we noticed suppression of TNF-α at 30 days
post short DLI PDT, that may suggest minimal macro-
phage recruitment due to extensive vascular mediated
damage, however this hypothesis warrants further
research. On the other hand, it would be reasonable to
hypothesize that longer DLI PDT that induces oxidative
stress within the tumors cells could have caused the noted
upregulation of angiogenic proteins such as bFGF, IFN-α
and -γ. Our earlier study on nasopharyngeal carcinoma
using HY-PDT showed upregulation of bFGF that has also
been attributed to PDT induced hypoxia [28]. In the same
way, upregulation of IFN-γ has been reported in a study
whereby antigen presenting cells from PDT-treated mice
exhibited an enhanced ability to stimulate T-cell prolifer-
ation and IFN-γ secretion [29].
The formation of new microvessels are mediated by the
endothelial cell adhesion molecules such as integrins,
selectins, cadherins and immunoglobulins [30] and the
lack of appropriate cell contacts may even lead the
endothelial cells to programmed cell death [31]. HY-PDT
induces extensive vascular and cellular damage at 24 h
time point, due to which an expected downregulation of
cell adhesion molecules, cadherin 5, collagen alpha 1 and
collagen alpha 3, intergrin alpha V and integrin beta 3 was
observed. However, when the PDT induced damage
diminished, upregulation of these molecules were noted.
Studies conducted recently have demonstrated that reac-
A – Expression of VEGF, TNF-α and IFN-α was detected in  the tumors using western immunoblot analysis Figure 5
A – Expression of VEGF, TNF-α and IFN-α was detected in 
the tumors using western immunoblot analysis. Expression of 
actin was used to monitor protein loading. Higher protein 
expression was detected in cellular targeted long DLI PDT at 
24 h compared to short DLI PDT at 24 h. TNF-α is secreted 
predominantly by the macrophages and its downregulaton at 
short DLI 30 days could suggest minimal macrophage recruit-
ment due to extensive vascular damage. At 30 days short and 
long DLI PDT comparable levels of IFN-α and VEGF was 
noticed. B – Ratio of VEGF, IFN-α and TNF-α density was 
plotted against actin. Compared to control, expression of 
proteins were statistically significant (p < 0.05) for all the 
groups except IFN-α at long DLI 30 days PDT group. Each 
group represents the mean (bars, SE) of 8 tumors.
Expression of angiogenic proteins in the treated tumors  were analysed using antibody arrays Figure 6
Expression of angiogenic proteins in the treated tumors 
were analysed using antibody arrays. Density of proteins 
were plotted and normalised against the positive control 
Actin. Each group represents the mean (bars, SE) of 8 tumors 
(i.e. one membrane was used per tumor). Compared to con-
trol tumors, VEGF secretion was significantly enhanced in all 
treatment groups (p < 0.05). In a similar way, compared to 
control tumors, greater bFGF secretion was noted in all 
groups (p < 0.05) except long DLI PDT at 24 h. IFN-γ 
expression was highest at 30 days post long DLI treatment. 
The inflammatory protein, IL-6 was upregulated in all the 
treatment groups except long DLI 30 days PDT.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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tive oxygen species produced during PDT eliminates
highly proliferating cells by damaging membranes and
affecting the extracellular matrix components profoundly,
especially the collagen matrix [31,32].
Hepatocyte growth factor/scatter factor (HGF), a cytokine
that stimulates tumor cell motility, invasion and angio-
genesis [33], was overexpressed in all the four treatment
groups. HGF receptor is a tyrosine kinase encoded by c-
met and activation of HGF/c-Met pathway is shown to
play a key role in tumor induced angiogenesis [34]. It has
also been reported that patients with urinary bladder can-
cer have elevated levels of HGF in urine and bladder can-
cer tissue [35]. Thus, our data suggests a functional role of
HGF in MGH bladder tumors. HGF also plays a promi-
nent role in the induction of the proangiogenic factors
PDGF, VEGF and IL-8 [36]. This suggests that the upregu-
lation of PDGFA could possibly be a result of the tran-
scriptional activation of PDGFA gene by HGF.
Significantly enhanced transcription of Ephrin A3 and
Ephrin B2 was observed 30 days post short and long DLI
PDT. These are classes of proteins that bind to the Eph
receptors, a subset of the endothelial cell receptor tyrosine
kinase (RTK), and promote cell attachment, cell-adhe-
sion, migration, capillary tube formation and ultimately
lead to tumor angiogenesis [37]. The Eph receptors also
regulate integrin-dependent cell adhesion through activa-
tion of the c-Jun kinase via Nck-interacting Ste20 kinase in
endothelial cells [38]. This further suggests that the down-
stream events in the Ephrin signaling can lead to
enhanced angiogenesis even at 30 days post PDT.
Transforming growth factor-alpha (TGFA) is another
growth factor that interacts with the same receptor as EGF
and induces mitogenic and cell differentiating responses
by binding to and activating surface EGF receptor (EGFR),
while high transcription activity of TGF-α and EGFR has
been reported in human tumors [39]. Though TGFA was
downregulated immediately post short and long DLI PDT,
EGF was found to be highly expressed at the initial time
point. However, when TGFA is upregulated 30 days post
PDT, EGF is downregulated. Thus it can be concluded that
at any time point, the multiple EGFR downstream intrac-
ellular signaling cascades are activated either by TGFA or
EGF in our HY-PDT treated tumors.
Neuropilin-2 (NRP-2) expression correlates with
advanced tumor stage and grade [40]. Neuropilins are
expressed in the tumor vasculature and in tumor cells, and
Table 1: Gene expression profiling was performed using Human Angiogenesis real time PCR Array. 
Gene Description Unigene Gene Bank Function
Cadherin 5, type 2, VE-cadherin Hs.76206 NM_001795 Plays an important role in cell adhesion and is crucial for vessel 
growth and maturation.
Collagen, type XVIII, alpha 1 Hs.517356 NM_030582 Component of extra-cellular matrix (ECM) that is important for 
tissue organization.
Collagen, type IV, alpha 3 Hs.570065 NM_000091
Integrin, alpha V Hs.436873 NM_002210 Cell adhesion molecules that plays a key role in tumor growth, 
angiogenesis and metastasis.
Integrin, beta 3 Hs.218040 NM_000212
Hepatocyte growth factor Hs.396530 NM_000601 Stimulates tumor cell motility, invasion and angiogenesis and its 
receptor is a tyrosine kinase encoded by c-met.
Ephrin-A3 Hs.516656 NM_004952 Ephrins are cell-membrane-bound ligands for Eph receptor tyrosine 
kinases and regulate a variety of developmental processes.
Platelet-derived growth factor alpha polypeptide Hs.645488 NM_002607 Stimulates endothelial cell proliferation.
Epidermal growth factor Hs.419815 NM_001963 An EGFR ligand, regulates cell growth, proliferation and 
differentiation.
Neuropilin 2 Hs.471200 NM_003872 Receptor for VEGF and semaphorin (SEMA) and is involved in 
angiogenesis and neuronal guidance.
Ephrin-B2 Hs.149239 NM_004093 An Eph ligand, promotes cell attachment, cell-adhesion, migration, 
capillary tube formation and tumor angiogenesis.
Jagged 1 Hs.224012 NM_000214 A notch ligand, it regulates a transmembrane ligand-receptor 
signaling pathway involved in the regulation of endothelial cell 
differentiation.
Tumor necrosis factor, alpha-induced protein 2 Hs.525607 NM_006291 A cytokine mainly produced by macrophages causes apoptotic cell 
death, cellular proliferation, differentiation and inflammation.
TEK tyrosine kinase, endothelial Hs.89640 NM_000459 Helps in vascular maturation, maintenance of integrity and 
remodeling.
Transforming growth factor, alpha Hs.170009 NM_003236 Binds to EGFR and is involved in tumorigenesis.
Vascular endothelial growth factor C Hs.435215 NM_005429 Involved in angiogenesis and lymphangiogenesis.
Selected genes that are involved in the angiogenesis pathway in HY-PDT treated tumors are listed below. The gene description, unigene entry, gene 
bank code and the function of each gene are described in the table.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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its upregulation at 24 h post PDT can be correlated to
tumor angiogenesis and tumor progression. Jagged 1
(JAG1) is a ligand for multiple Notch receptors and is
involved in the mediation of Notch signaling that con-
trols multiple cell differentiation processes [41]. Down-
regulation of JAG1, a notch ligand in all treatment groups
could suggest that PDT could suppress the notch signaling
cascade. TEK (tyrosine kinase, endothelial cell), also
known as TIE-2, constitute a subfamily of receptor tyro-
sine kinase, known for its specific expression in vascular
endothelial cells [42]. In the present study the TEK gene
was found to be upregulated 30 days post short and long
DLI PDT. Thus it can be speculated that the expression of
this tyrosine kinase would further signal the downstream
pathway leading to cell proliferation, migration and sur-
vival [43]. These results suggest that Ang1/Tie2 signaling
plays an important role in endothelial cell survival post
HY-PDT.
The enhanced angiogenic effect at 30 days post PDT can
be attributed to the increased expression of angiogenic
growth factors and receptors such as HGF, TGFA, PDGFA,
VEGFC and TEK. The angiogenic process is often triggered
by proangiogenic factors such as VEGF, PDGF, TGFA, EGF
and bFGF [44]. VEGF is the most pivotal positive proang-
iogenic regulator detected in various tumors [45] and has
the ability to elicit multiple responses depending upon
the context of its expression and the presence of other
growth factors. High VEGF mRNA transcription at 30 days
post PDT could suggest its major role in tumor angiogen-
esis. Gomer et al. [17] have previously reported that PDT
induced hypoxia triggers cytokine expression. Consistent
with this study, we have reported that PDT induced
Table 2: Gene expression profiling was performed for HY-PDT treated tumors. 
Gene Gene Symbol Short DLI PDT 24 h Long DLI PDT 24 h
Fold change p-value Up(↑)/down (↓) 
regulation
Fold change p-value Up (↑)/down (↓) 
regulation
Adhesion molecules
Cadherin 5, type 2, VE-
cadherin
CDH5 0.080 0.015 ↓ 0.214 0.0313 ↓
Collagen, type XVIII, 
alpha 1
COL18A1 0.016 0.0335 ↓ 0.024 0.051 ↓
Collagen, type IV, alpha 3 COL4A3 0.006 0.0075 ↓ 0.027 0.027 ↓
Integrin, alpha V ITGAV 0.0007 0.00003 ↓ 0.086 0.029 ↓
Integrin, beta 3 ITGB3 0.169 0.027 ↓ 0.144 0.025 ↓
Growth factors and 
receptors
Hepatocyte growth 
factor
HGF 30.70 0.00008 ↑ 8.04 0.0014 ↑
Ephrin-A3 EFNA3 12.76 0.026 ↑ 12.47 0.035 ↑
Platelet-derived growth 
factor alpha polypeptide
PDGFA 10.15 0.038 ↑ 22.68 0.0109 ↑
Epidermal growth factor EGF 7.013 0.003 ↑ 0.051 0.017 ↓
Neuropilin 2 NRP2 5.502 0.031 ↑ 5.993 0.012 ↑
Ephrin-B2 EFNB2 0.003 0.0002 ↓ 0.205 0.039 ↓
Jagged 1 JAG1 0.001 0.008 ↓ 0.004 0.021 ↓
Tumor necrosis factor, 
alpha-induced protein 2
TNFAIP2 3.34 0.045 ↑ 0.136 0.031 ↓
TEK tyrosine kinase, 
endothelial
TEK 0.250 0.042 ↓ 0.218 0.0028 ↓
Transforming growth 
factor, alpha
TGFA 0.054 0.030 ↓ 0.018 0.0106 ↓
Vascular endothelial 
growth factor C
VEGFC 0.0031 0.003 ↓ 0.023 0.013 ↓
The gene symbol, fold-change, p-value and the status of transcription have been described for each gene. The genes involved in the angiogenesis 
pathway were divided into two groups – adhesion molecules and growth factors and receptors. Six genes regulating the angiogenesis pathway i.e., 
HGF, EFNA3, EGF, NRP2, PDGFA and TNFAIP2 were upregulated in both short and long DLI 24 h HY-PDT with the exception of EGF in long DLI 
HY-PDT and 10 genes CDH5, COL18A1, COL4A3, EFNB2, ITGAV, ITGB3, TEK, TGFA, VEGFC and JAG1 were downregulated in both short and 
long 24 h HY-PDT when compared with the controls (p values are given in the table).Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
Page 10 of 14
(page number not for citation purposes)
inflammation and hypoxia upregulates various cytokines
and proangiogenic factors, i.e., VEGF, bFGF and EGF [20].
Conclusion
In summary, we have established that differential expres-
sion of genes could be a result of the interval between
photosensitizer administration and light activation. Our
results indicate that predominantly cellular targeting long
DLI PDT can induce greater expression of angiogenic pro-
teins compared to vascular targeting short DLI PDT. Col-
lectively, we observed upregulation of 4 genes at 24 h post
HY-PDT and 10 genes at 30 days post HY-PDT, indicating
a greater need for combination therapy by including anti-
angiogenic agents that target specific pathways.
Methods
Photosensitizer
The photosensitizer HY (Molecular Probes, OR, USA) was
dissolved in dimethyl sulfoxide, DMSO (Sigma Aldrich
Inc, St Louis Mo, USA) and diluted in phosphate-buffered
saline (PBS) and administered intravenously at a dose of
5 mg/kg.
Cell culture conditions and xenograft tumor model
Male balb/c nude mice, 6–8 weeks of age, weighing an
average of 24–25 g were obtained from the Animal
Resource Centre, Western Australia. To establish a murine
xenograft model of human bladder carcinoma, the
present study used MGH epithelial bladder cell line.
Briefly, cells were cultured as a monolayer in RPMI-1640
medium. Approximately 3.0 × 106 MGH bladder cells sus-
pended in 150 μl of Hanks' balanced salt solution (Gibco,
USA) were injected subcutaneously into the lower flanks
Table 3: At 30 days post HY-PDT 12 genes COL18A1, CDH5, ITGB3, VEGFC, HGF, TGFA, PDGFA, TEK, EFNA3, EFNB2, NRP2 and 
TNFAIP2 exhibited higher transcriptional activity at both short and long DLI 30 days PDT with the exception of NRP2 and TEK in 
cellular mediated long DLI PDT at 30 days. 
Gene Gene Symbol Short DLI PDT 30 days Long DLI PDT 30 days
Fold change p-value Up (↑)/down (↓) 
regulation
Fold change p-value Up (↑)/down (↓) 
regulation
Adhesion molecules
Collagen, type XVIII, 
alpha 1
COL18A1 46.21 0.041 ↑ 39.40 0.047 ↑
Cadherin 5, type 2, VE-
cadherin
CDH5 13.80 0.003 ↑ 10.51 0.0022 ↑
Integrin, beta 3 ITGB3 8.86 0.021 ↑ 7.568 0.023 ↑
Integrin, alpha V ITGAV 0.186 0.009 ↓ 8.654 0.006 ↑
Collagen, type IV, alpha 3 COL4A3 0.022 0.018 ↓ 0.0416 0.035 ↓
Growth factors and 
receptors
Vascular endothelial 
growth factor C
VEGFC 25.05 0.028 ↑ 19.84 0.034 ↑
Hepatocyte growth 
factor
HGF 23.86 0.040 ↑ 8.476 0.0013 ↑
Transforming growth 
factor, alpha
TGFA 16.34 0.035 ↑ 28.18 0.02 ↑
Platelet-derived growth 
factor alpha polypeptide
PDGFA 11.88 0.02 ↑ 8.206 0.04 ↑
TEK tyrosine kinase, 
endothelial
TEK 10.34 0.047 ↑ 0.248 0.007 ↓
Ephrin-A3 EFNA3 9.65 0.037 ↑ 13.77 0.034 ↑
Ephrin-B2 EFNB2 6.85 0.02 ↑ 9.254 0.043 ↑
Neuropilin 2 NRP2 7.345 0.026 ↑ 0.045 0.013 ↓
Tumor necrosis factor, 
alpha-induced protein 2
TNFAIP2 5.515 0.010 ↑ 16 0.003 ↑
Jagged 1 JAG1 0.015 0.041 ↓ 0.0146 0.040 ↓
Epidermal growth factor EGF 0.211 0.012 ↓ 0.0963 0.006 ↓
4 genes ITGAV, COL4A3, JAG1 and EGF were downregulated at 30 days for both short and long DLI PDT with exception of ITGAV in long DLI 
HY-PDT.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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of the mice. The mice were kept for 10–14 days to allow
the tumors to grow till they were palpably greater than 5–
6 mm. The tumor volume was calculated using the follow-
ing formula: volume = (π/6 × d1 × d2 × d3), where d1, d2
and d3 are tumor dimensions in 3 orthogonal directions.
All procedures carried out in this study were approved by
the Institutional Animal Care and Use Committee
(IACUC), SingHealth, Singapore and were conducted in
accordance with international standards.
Fluorescence imaging
A dose of 5 mg/kg of hypericin was administered to mice
through tail vein injections. The mice were anesthetized
using 1:1 vol/vol cocktail of ketamine hydrochloride (Trit-
tau, Germany) and valium (David Bull Laboratories, Aus-
tralia). The skin overlaying the tumor was carefully
removed to expose the tumor and imaging was performed
at 0.5 and 6 h post hypericin administration. A fluores-
cence endoscope system (Karl Storz, Tuttlingen, Ger-
many) was used to perform macroscopic fluorescence
digital imaging. This system consists of a fluorescence
detection unit, an illumination console, a video display-
ing and recording unit, and a computing system for image
acquisition, display and processing. The D-Light system
contains an excitation filter (375–440 nm) that allows
high transmission in the violet part of the spectrum and
blocks the rest of the visible part of the spectrum. The flu-
orescence can be detected since a large portion of the exci-
tation light is being blocked by an observation filter (cut-
off wavelength at 470 nm). An optical filter is located in
the eyepiece of the fluorescence endoscope (Karl Storz,
Hopkins II 0°, 4 mm) and it reduces blue light excitation
that is diffusely back-scattered by the tissue and transmits
red fluorescent light. The images thus obtained were ana-
lysed using the image analysis software, MicroImage 4.0.
Images obtained in blue light needed to be further proc-
essed to obtain normalized fluorescence intensity images.
The processing involves contrast enhancement of the orig-
inal image. This is followed by hue extraction where the
fluorescence color (red) is extracted. Following hue extrac-
tion, the thresholding and segmentation of the area of
interest (AOI) was carried out. This gives us the red-black
image, from the red-black image we obtained the relative
intensity distribution over the tumor and the normal
regions. Finally, the normalized intensity image, which is
the ratio of the tumor fluorescence to the normal (blue)
background, was obtained. The ratio of red intensity over
blue intensity from 10 images per group was quantified
using the software and the graph was plotted.
Laser confocal fluorescence imaging
After intravenous administration of hypericin the animals
were sacrificed at 0.5 and 6 h and tumors were subse-
quently extracted. The tumors were then snap frozen in
liquid nitrogen. Cryosections of 20 μm thickness were
obtained using a microtome cryostat (Cryo-Star HM 560
MV, Germany) and the sections were mounted onto
slides. A laser confocal fluorescence microscope (Meta
LSM 510, Carl Zeiss, Germany) was used to obtain confo-
cal fluorescence images. A 488 nm Argon laser was used to
excite the tissue. Fluorescence emissions in the wave-
length range of 590–630 nm were spilt by a diachronic fil-
ter and detected through a band-pass filter (BP-610 nm,
Omega Optical, USA). Each fluorescence image of any
field was reconstructed from a sequence of 20 sequential
optical images. Voltage gain, PMT voltage and sensitivity
(contrast, brightness and filters) were fixed for all fields
and slides imaged. Fluorescence data analysis was carried
out using an image software package (Kontron KS400,
version 3.0, Hallbergmoos, Germany). A total of 10
images, acquired from different tumor samples, were used
to quantify fluorescence intensity. Briefly, digital quantifi-
cation was carried out by using box superimposition of an
area of 100 pixels, or contour super-imposition where the
contour of the area of interest was outlined and the pixel
intensities per unit area determined. This was done to
determine the relative hypericin fluorescence between dif-
ferent regions of the same specimen.
PDT treatment protocol
Animals were assigned to five different groups: (i) control
(untreated tumor), (ii) short DLI PDT 24 h, (iii) long DLI
PDT 24 h, (iv) short DLI PDT 30 days and (v) long DLI
PDT 30 days, and each group comprised of 10 animals.
Tumors from groups (ii) and (iii) were extracted at 24 h
post PDT whereas tumors from groups (iv) and (v) were
extracted at 30 days post PDT. The PDT treatment groups
received intravenous injection of HY followed by irradia-
tion with a light source consisting of broadband halogen
light (Zeiss KL1500) fitted with a customized 560–640
nm band-pass filter. A light dosage of 120 J/cm2 and 100
mW/cm2 was used for PDT treatment. It should be noted
that only the DLI was varied, the photosensitizer dose was
maintained for all the treated groups.
Tumor tissue lysate preparation
At the designated time points of 24 h and 30 days post
PDT, the mice were humanely sacrificed. The tumor tis-
sues were then harvested and immediately frozen in liq-
uid nitrogen. The tissues were then crushed into powder
in liquid nitrogen and ice-cold lysis buffer (T-PER, Pierce)
with protease inhibitor (Complete Mini, Roche) was
added and then kept on ice for 30 min. After subsequent
centrifugation at 14,000 × g for 15 min at 4°C, superna-
tants (total tumor cell lysates) were stored at -70°C. The
protein concentration was estimated by DC Bio-Rad assay
in accordance with to the manufacturer's protocol.Molecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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Immunohistochemistry
Tumor tissues from both control and HY-PDT treated ani-
mals were used for immunohistochemistry. Immunohis-
tochemical staining was done using the Chemicon Blood
vessel staining kit on formalin-fixed, paraffin-embedded
control and HY-PDT tumor tissues. Sections were incu-
bated with anti-CD31 (1:100) for 1 h followed by incuba-
tion with anti-rabbit secondary antibodies conjugated to
horseradish peroxidase-linked labeled polymers. 3,3'-
Diaminobenzidine-positive substrate-chromogen was
added to sections and incubated for 5 minutes for color
development. Finally, the slides were counterstained with
Harris's haematoxylin for 5 seconds, dehydrated, and
mounted. Primary antibody was replaced with normal
mouse serum IgG1 (1:500) to confirm the specificity and
served as negative control. Microvessels stained with
CD31 were counted by light microscopy at X200 magnifi-
cation. Any stained endothelial cell or cell cluster clearly
separated from adjacent vessels was considered a single
countable microvessel. Slides were examined by two inde-
pendent observers. IHC scoring was performed based on
the prevalence of CD31 staining within the tumor (No
staining = 0, < 10% staining = 1, 10–25% = 2, 25–50% =
3, 50–75% = 4 and 75–100% = 5). Images from the slides
were captured using image processing software (Kontron
KS400, version 3.0, Hallbergmoos, Germany).
Western blotting
For Western blot analysis, 30 μg of protein were resolved
on 10–12% polyacrylamide-SDS gels and transferred onto
a nitrocellulose membrane as described elsewhere. The
membrane was immersed in blocking buffer (5% non-fat
dry milk/1% Tween 20 in 20 mM TBS, pH 7.5) for 1.5 h
at room temperature and incubated with the appropriate
primary antibody i.e., mouse monoclonal anti-TNF-α (1:
50) and IFN-α (1:100) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and mouse monoclonal anti-human
VEGF (1:100) (BD Pharmingen, BD Biosciences, CA,
USA) solved in blocking buffer overnight at 4°C, followed
by incubation with complementary secondary antibody.
Proteins were detected by chemiluminescence (Supersig-
nal, Pierce Technology, Rockford, IL, USA) and autoradi-
ography using Hyperfilm ECL (Amersham Biosciences,
UK).
Detection of angiogenesis proteins using antibody array
Expression of angiogenesis proteins following HY-PDT
were measured using the RayBio® Human Angiogenesis
Antibody Array 1.1 (RayBiotech Inc, USA) in control and
PDT subjects (8 control and 8 HY-PDT) using one array
per tissue sample. Only expressions of proteins relevant to
this study are reported in this article. The components in
the kit included protein array membranes, biotin-conju-
gated anti-cytokines, HRP-conjugated streptavidin and
detection buffer. Briefly, the protein array membranes
were immersed in blocking buffer, after which the mem-
branes were incubated with tumor lysate for 2 h. After
extensive washing the membrane was incubated with pri-
mary antibody and after further washing the HRP-conju-
gated streptavidin was added and incubated for another 2
h. After adding the detection buffer, the membranes were
exposed to X-ray film (Hyperfilm ECL, Amersham Bio-
sciences UK) and the signal was detected using film devel-
oper (Kodak M35 OMAT Processor). The intensities of the
signal were quantified using a densitometer. By compar-
ing the intensities of the signals, the relative expression
levels of the angiogenic proteins were analyzed. The
results were normalized to an internal positive control
provided on each membrane. RayBio Analysis Tool, a pro-
gram specifically designed for the analysis of antibody
arrays, was used to plot the graphs.
RNA isolation and cDNA preparation
Total RNA was extracted from tumor tissue using the com-
mercially available Nucleospin RNA II kit (Macherey-
Nagel, Germany). Briefly, the frozen tissue samples were
crushed into powder using liquid nitrogen and lysis
buffer, and β-mercaptoethanol was added to prepare the
lysate. The lysate was then filtered and 70% ethanol was
added to adjust RNA binding to the columns. Later DNA
digestion was performed and pure RNA was eluted. RNA
quality and purity was checked using UV Spectrophotom-
etry and by detecting the ribosomal RNA integrity. Com-
plementary DNA (cDNA) was synthesized from 2 μg
DNA-free total RNA before PCR analysis.
Gene expression profiling using real-time PCR array
The Human Angiogenesis RT2 Profiler™ PCR Array (Super-
Array, USA) was used to identify the expression of 84 key
genes involved in modulating the biological processes of
angiogenesis. The array includes growth factors and their
receptors, chemokines and cytokines, matrix and adhe-
sion molecules, proteases and their inhibitors as well as
transcription factors, involved in angiogenesis. For each
PCR evaluation, amplification and detection was per-
formed with the ABI Prism 7000 Sequence Detection Sys-
tems (Applied BioSystems, USA). Average ΔCt value for
each gene across triplicate arrays for each treatment group
was calculated. ΔΔCt for each gene across control and
experimental group were determined. Finally the fold
change was computed for each gene from control and
other groups as 2^(-ΔΔCt).
Statistics analyses
Statistical analysis was performed using GraphPad Prism
version 4.0 (GraphPad Software, Inc., San Diego, CA,
USA). One-way ANOVA was used to analyze the variance
and Bonferroni's multiple comparison test was used to
compare the significance between all the groups for the
various experiments. Dunnett's multiple comparison testsMolecular Cancer 2008, 7:56 http://www.molecular-cancer.com/content/7/1/56
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was used to analyze the difference between control and
the other groups. A p value of < 0.05 was considered to be
significant.
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